Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells

Biochemical Pharmacology

Volumn 53, Issue 11, 1997, Pages 1719-1724

  Parsons, P G ^a   Hansen, C ^a   Fairlie, D P ^b   West, M L ^b   Danoy, P A C ^a   Sturm, R A ^b   Dunn, I S ^b   Pedley, J ^a   Ablett, E M ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Azelaic bishydroxamic acid; Differentiation; Human melanoma; Selective toxicity; Transcription

Indexed keywords

AZELAIC ACID; AZELAIC BISHYDROXAMIC ACID; HEXAMETHYLENEBISACETAMIDE; HYDROXAMIC ACID; METALLOTHIONEIN; MONOPHENOL MONOOXYGENASE; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; NEWBORN; ONCOGENE C FOS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ACETAMIDES; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TRANSFORMED; CELL SURVIVAL; DICARBOXYLIC ACIDS; GENES, REPORTER; HUMANS; HYDROXAMIC ACIDS; INTERFERON TYPE I; MELANOCYTES; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; OXIDOREDUCTASES; PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030786371     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00016-6     Document Type: Article

References (21)

1. Reuben RC, Khanna PL and Gazitt Y, A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci 72: 1003-1006, 1975.
2. Marks PA, Richon VM, Kiyokawa H and Rifkind RA, Inducing differentiation of transformed cells with hybrid polar compounds: A cell-cycle dependent process. Proc Natl Acad Sci USA 91: 10251-10254, 1994.
3. Richon VM, Ramsay RG, Rifkind RA and Marks PA, Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythrleukemia cell differentiation. Oncogene 4: 165-173, 1989.
4. Richon VM, Rifkind RA and Marks PA, Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth Diff 3: 413-420, 1992.
5. Kiyokawa H, Richon VM, Rifkind RA and Marks PA, Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol 14: 7195-7203, 1994.
6. Breslow R, Jursic B, Yan ZF, Freidman E, Leng L, Ngo L, Rifkind RA and Marks P, Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci 88: 5542-5546, 1991.
7. Takahashi H and Parsons PG, In vitro phenotypic alteration of human melanoma cells induced by differentiating agents: Heterogeneous effects on cellular growth and morphology, enzymatic activity and antigenic expression. Pigm Cell Res 3: 223-232, 1990.
8. Sturm RA, O'Sullivan BJ, Thomson JAF, Jamshidi N, Pedley J and Parsons PG, Expression studies of pigmentation and pou-domain genes in human melanoma cells. Pigm Cell Res 7: 235-240, 1994.
9. McEwan M, Parsons PG and Moss DJ, Monoclonal antibody against human tyrosinase and reactive with melanotic and amelanotic melanoma cells. J Invest Dermatol 90: 515-519, 1988.
10. Wong SSC, Sturm RA, Michel J, Zhang X-M, Danoy PAC, McGregor K, Jacobs JJ, Kaushal A, Dong Y, Dunn IS and Parsons PG, Transcriptional regulation of differentiation, selective toxicity and ATGCAAAT binding of bisbenzimidazole derivatives in human melanoma cells. Biochem Pharmacol 47: 827-837, 1994.
11. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A and Fusenig NE, Normal keratinisation in a spontaneously immortalised aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771, 1988.
12. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW, A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871, 1992.
13. Taylor GO and Dunn IS, Automated cycle sequencing of PCR templates: relationships between fragment size, concentration and strand renaturation rates on sequencing efficiency. DNA Sequencing 5: 9-15, 1994.
14. Vijayasaradhi S, Doskoch PM, Wolchok J and Houghton AN, Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation. J Invest Dermatol 105: 113-119, 1995.
15. Vijayasaradhi S, Doskoch PM and Houghton AN, Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res 196: 233-240, 1991.
16. Edwards DR, Cell signalling and the control of gene transcription. Trends Pharm Sci 15: 239-244, 1994.
17. Liu J, McKim JM Jr, Liu YP, Klaassen CD, Effects of butyrate homologues on metallothionein induction in rat primary hepatocyte cultures. In Vitro 28A: 320-326, 1992.
18. Biard DS, Cordier A and Sarasin A, Establishment of a human cell line for the detection of demethylating agents. Exp Cell Res 200: 263-271, 1992.
19. Hamer DH, Metallothionein. Ann Rev Biochem 55: 913-951, 1986.
20. Ou CZ and Ebadi M, Pineal and retinal protein kinase C isoenzymes: Cooperative activation by calcium and zinc metallothionein. J Pineal Res 12: 17-26, 1992.
21. Vidal MJ, Loganzo F, de Oliveira AR, Hayward NK and Albino AP, Mutations and defective expression of the WAF1 p21 tumor-suppressor gene in malignant melanomas. Melanoma Res 5: 243-250, 1995.